Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
53
NAGE Quote, Financials, Valuation and Earnings
Last price:
$6.74
Seasonality move
:
21.45%
Day range:
$6.43 - $6.60
52-week range:
$5.16 - $14.69
Dividend yield:
0%
P/E ratio:
26.84x
P/S ratio:
4.42x
P/B ratio:
7.37x
Volume:
789.3K
Avg. volume:
794.1K
1-year change:
20.7%
Market cap:
$521.1M
Revenue:
$99.6M
EPS (TTM):
$0.24
Analysts' Opinion
-
Consensus RatingNiagen Bioscience, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.80, Niagen Bioscience, Inc. has an estimated upside of 141.96% from its current price of $6.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $6.53.
Fair Value
-
According to the consensus of 5 analysts, Niagen Bioscience, Inc. has 141.96% upside to fair value with a price target of $15.80 per share.
NAGE vs. S&P 500
-
Over the past 5 trading days, Niagen Bioscience, Inc. has overperformed the S&P 500 by 0.05% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Niagen Bioscience, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Niagen Bioscience, Inc. has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Niagen Bioscience, Inc. reported revenues of $34M.
Earnings Growth
-
Niagen Bioscience, Inc. has grown year-over-year earnings for 13 quarters straight. In the most recent quarter Niagen Bioscience, Inc. reported earnings per share of $0.05.
Enterprise value:
459.9M
EV / Invested capital:
6.24x
Price / LTM sales:
4.42x
EV / EBIT:
23.82x
EV / Revenue:
3.69x
PEG ratio (5yr expected):
0.02x
EV / Free cash flow:
21.80x
Price / Operating cash flow:
26.14x
Enterprise value / EBITDA:
22.71x
Gross Profit (TTM):
$79.7M
Return On Assets:
25.81%
Net Income Margin (TTM):
16.38%
Return On Equity:
37.74%
Return On Invested Capital:
35.7%
Operating Margin:
12.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $83.4M | $91.7M | $124.7M | $25.6M | $34M | |
| Gross Profit | $49.9M | $56.3M | $79.7M | $16.2M | $21.9M | |
| Operating Income | -$4.6M | $3.6M | $19.3M | $2.8M | $4.2M | |
| EBITDA | -$2.8M | $5.1M | $20.2M | $3.2M | $4.4M | |
| Diluted EPS | -$0.09 | $0.02 | $0.24 | $0.02 | $0.05 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $52.8M | $37.9M | $47.2M | $52.1M | $93.6M | |
| Total Assets | $60.5M | $45.7M | $53.5M | $56.5M | $98.1M | |
| Current Liabilities | $17.8M | $16.7M | $19.4M | $17.7M | $22.7M | |
| Total Liabilities | $25M | $24.6M | $26.2M | $22.2M | $27.5M | |
| Total Equity | $35.4M | $21M | $27.3M | $34.4M | $70.7M | |
| Total Debt | $2.9M | $3.7M | $2.9M | $1.9M | $2.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $6.1M | $4.1M | $21.4M | $3.5M | $3.7M | |
| Cash From Investing | -$294K | -$95K | -$260K | -$21K | -$24K | |
| Cash From Financing | $7.7M | $1.6M | $10.8M | $1M | $148K | |
| Free Cash Flow | $5.8M | $4M | $21.1M | $3.5M | $3.7M | |
NAGE
Sector
Market Cap
$521.1M
$27.9M
Price % of 52-Week High
44.45%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-1.45%
-1.49%
1-Year Price Total Return
20.7%
-16.66%
Beta (5-Year)
2.308
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.47
200-day SMA
Sell
Level
$8.94
Bollinger Bands (100)
Sell
Level
6.78 - 9.56
Chaikin Money Flow
Buy
Level
12M
20-day SMA
Sell
Level
$6.60
Relative Strength Index (RSI14)
Sell
Level
44.51
ADX Line
Sell
Level
9.39
Williams %R
Neutral
Level
-44.8598
50-day SMA
Sell
Level
$6.96
MACD (12, 26)
Sell
Level
-0.18
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
162M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.0088)
Buy
CA Score
(Annual)
Level (1.2171)
Sell
Beneish M-Score
(Annual)
Level (-1.0225)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-2.2498)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Stock Forecast FAQ
In the current month, NAGE has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NAGE average analyst price target in the past 3 months is $15.80.
-
Where Will Niagen Bioscience, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Niagen Bioscience, Inc. share price will rise to $15.80 per share over the next 12 months.
-
What Do Analysts Say About Niagen Bioscience, Inc.?
Analysts are divided on their view about Niagen Bioscience, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Niagen Bioscience, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Niagen Bioscience, Inc.'s Price Target?
The price target for Niagen Bioscience, Inc. over the next 1-year time period is forecast to be $15.80 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NAGE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Niagen Bioscience, Inc. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NAGE?
You can purchase shares of Niagen Bioscience, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Niagen Bioscience, Inc. shares.
-
What Is The Niagen Bioscience, Inc. Share Price Today?
Niagen Bioscience, Inc. was last trading at $6.74 per share. This represents the most recent stock quote for Niagen Bioscience, Inc.. Yesterday, Niagen Bioscience, Inc. closed at $6.53 per share.
-
How To Buy Niagen Bioscience, Inc. Stock Online?
In order to purchase Niagen Bioscience, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get NAGE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NAGE
Sector
P/E ratio
26.84x
23.85x
PEG ratio
0.02x
-0.01x
P/B ratio
7.37x
1.81x
Price / LTM sales
4.42x
1.58x
Growth Metrics
NAGE
Sector
Revenue growth
32.86%
4.62%
Earnings growth
118.18%
10.7%
Revenue (5-year growth)
16.56%
6.5%
Earnings forecast
$0.02
-$0.21
Profitability
NAGE
Sector
Profitability FY 2024
$61.6M
$3.6M
Return on invested capital
35.7%
-31.87%
Return on assets
25.81%
-28.18%
Return on equity
37.74%
-37.63%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Mar
4
Estimated Next Earnings Date
Feb
3
Balance Sheet
NAGE
Sector
Total cash
$64.3M
$26.4M
Short term investments
--
$25.7M
Total assets
$68.3M
$76.9M
Long term debt
$2.1M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
